DENTSPLY SIRONA Inc. (XRAY) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $10.09: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend.
Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into approximately 140 countries through Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare... Read more
Sell if holding. Engine safety override at $10.09: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 48. Score 4.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — DENTSPLY SIRONA Inc.
Latest news
- NEWS DENTSPLY SIRONA Appoints John Forston CFO, Effective July 20 — benzinga Jun 11, 2026 neutral
- NEWS Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields — benzinga May 29, 2026 neutral
- NEWS Dentsply Sirona Expands Collaboration With Nashville Dental To Expand U.S. Distribution Footprint — benzinga May 26, 2026 positive
- NEWS Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $14 — benzinga May 6, 2026 negative
- NEWS Dentsply Sirona Q1 2026 Earnings Call Transcript — benzinga May 5, 2026 neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerHenry Schein, Inc.13%10-K Item 1: 'Henry Schein, Inc. ... 13 | %'
Material Events(8-K, last 90d)
- 2026-02-24Item 5.02LOWBoard increased from 11 to 13 directors; James D. Forbes and Brian P. McKeon appointed effective February 27, 2026. Forbes to Compensation & Human Capital Committee; McKeon to Audit/Finance and Science & Technology Committees. Routine board expansion; no officer departures.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -17.1%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.09: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 48. Prior stop was $9.38. Score 4.7/10, moderate confidence.
Take-profit target: $12.06 (+19.5% upside). Prior stop was $9.38. Stop-loss: $9.38.
Quality below floor (3.5 < 4.0).
DENTSPLY SIRONA Inc. trades at a P/E of N/A (forward 6.5). TrendMatrix value score: 8.7/10. Verdict: Sell.
22 analysts cover XRAY with a consensus score of 3.4/5. Average price target: $13.
What does DENTSPLY SIRONA Inc. do?Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into...
Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, selling into approximately 140 countries through Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare segments. Revenue comes from equipment, consumables, software, and continence care products; Henry Schein accounted for 13% of 2025 net sales.